Moderna (NASDAQ:MRNA) is scheduled to report its quarterly earnings on Friday, May 1, 2026. The company currently holds a market capitalization of $18 billion and has generated revenue of $1.9 billion over the last twelve months. Financially, Moderna remains operationally loss-making with operating losses of...
Moderna Inc. (MRNA) experienced a significant decline in its stock price, recording an 18% drop over a five-day losing streak that resulted in a market capitalization reduction of approximately $3.9 billion. The company's market cap now stands at $18 billion. Trefis highlights concerns regarding Moderna's...
Moderna (MRNA), a developer of mRNA-based therapeutics and vaccines, has experienced a significant decline in its stock price over the past five trading days. The company's shares have fallen 18% cumulatively during this losing streak, resulting in an approximate $3.9 billion reduction in its market...
Moderna Inc. stock recently entered its fifth consecutive day of losses, resulting in an 18% cumulative decline over the five-day period as of the article's publication on April 30, 2026. During this streak, the company's market capitalization dropped by approximately $3.9 billion, reducing its valuation...
Biotechnology company Moderna (NASDAQ: MRNA) is preparing to report earnings this Friday morning, with market expectations for a significant shift from last year's performance. Analysts anticipate Moderna’s revenue will grow 131% year on year, marking a reversal from the 35.3% decrease recorded in the same...
